Peter Doshi

5.7k total citations · 2 hit papers
91 papers, 3.0k citations indexed

About

Peter Doshi is a scholar working on Epidemiology, Public Health, Environmental and Occupational Health and Pharmacology. According to data from OpenAlex, Peter Doshi has authored 91 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Epidemiology, 26 papers in Public Health, Environmental and Occupational Health and 22 papers in Pharmacology. Recurrent topics in Peter Doshi's work include Influenza Virus Research Studies (28 papers), Pharmaceutical industry and healthcare (20 papers) and Meta-analysis and systematic reviews (14 papers). Peter Doshi is often cited by papers focused on Influenza Virus Research Studies (28 papers), Pharmaceutical industry and healthcare (20 papers) and Meta-analysis and systematic reviews (14 papers). Peter Doshi collaborates with scholars based in United States, Australia and United Kingdom. Peter Doshi's co-authors include Tom Jefferson, Mark Jones, Chris Del Mar, Carl Heneghan, Rokuro Hama, Matthew Thompson, T. Jefferson, Igho Onakpoya, Elizabeth Spencer and Liz Dooley and has published in prestigious journals such as The Lancet, Annals of Internal Medicine and American Journal of Public Health.

In The Last Decade

Peter Doshi

89 papers receiving 2.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children

2012 432 citations Tom Jefferson, Mark Jones et al. Cochrane Database of Systematic Reviews profile →
Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults

2022 111 citations Mark Jones, Peter Doshi et al. profile →

Peers

Countries citing papers authored by Peter Doshi

Since Specialization

Citations

This map shows the geographic impact of Peter Doshi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Doshi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Doshi more than expected).

Fields of papers citing papers by Peter Doshi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Doshi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Doshi. The network helps show where Peter Doshi may publish in the future.

Co-authorship network of co-authors of Peter Doshi

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Doshi. A scholar is included among the top collaborators of Peter Doshi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Doshi. Peter Doshi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Development and Evaluation of a Framework for Identifying and Addressing Spin for Harms in Systematic Reviews of Interventions 2024 ·Annals of Internal Medicine ·Riaz Qureshı, (unknown), (unknown), Evan Mayo‐Wilson, Matthew J. Page, Victoria Cornelius, Roger Chou, Isabelle Boutron, Su Golder, Lisa Bero, Peter Doshi, Matt Vassar, Reint Meursinge Reynders, Tianjing Li	1
2	Sources of bias in observational studies of covid‐19 vaccine effectiveness 2023 ·Journal of Evaluation in Clinical Practice ·(unknown), Mark Jones, Peter Doshi	22
3	The FDA and Moderna’s cosy relationship: how lax rules enable a revolving door culture 2023 ·BMJ ·Peter Doshi	0
4	Evaluation of Publicly Available Information on Sex-Related Differences in the Efficacy and Safety of Newly Approved Medications 2022 ·Journal of General Internal Medicine ·(unknown), (unknown), Hazem E. Hassan, Peter Doshi	0
5	Antibiotics Approved for Marketing in Populations Specifically Excluded From Premarketing Trials, 1999–2018 2020 ·Mayo Clinic Proceedings ·(unknown), John H. Powers, Peter Doshi	3
6	FDA to begin releasing clinical study reports in pilot programme 2018 ·BMJ ·Peter Doshi	4
7	When to include clinical study reports and regulatory documents in systematic reviews 2018 ·BMJ evidence-based medicine ·Tom Jefferson, Peter Doshi, Isabelle Boutron, Su Golder, Carl Heneghan, Alexander Hodkinson, Mark Jones, Carol Lefebvre, Lesley Stewart	17
8	The use of clinical study reports to enhance the quality of systematic reviews: a survey of systematic review authors 2018 ·Systematic Reviews ·Alexander Hodkinson, Kristina Charlotte Dietz, Carol Lefebvre, Su Golder, Mark Jones, Peter Doshi, Carl Heneghan, Tom Jefferson, Isabelle Boutron, Lesley Stewart	20
9	Open data 5 years on: a case series of 12 freedom of information requests for regulatory data to the European Medicines Agency 2016 ·Trials ·Peter Doshi, Tom Jefferson	20
10	No correction, no retraction, no apology, no comment: paroxetine trial reanalysis raises questions about institutional responsibility 2015 ·BMJ ·Peter Doshi	13
11	North American regulatory agencies can and should make clinical trial data publicly available 2015 ·Canadian Medical Association Journal ·Nav Persaud, Peter Doshi	5
12	Un fallimento multisistemico: la storia dei farmaci antinfluenzali 2014 ·Recenti Progressi in Medicina ·Tom Jefferson, Peter Doshi	1
13	Commentary on Cochrane review of neuraminidase inhibitors for preventing and treating influenza in healthy adults and children 2014 ·Clinical Microbiology and Infection ·Mark Jones, Tom Jefferson, Peter Doshi, Chris Del Mar, Carl Heneghan, Igho Onakpoya	9
14	Clinical study reports of randomised controlled trials: an exploratory review of previously confidential industry reports 2013 ·BMJ Open ·Peter Doshi, Tom Jefferson	57
15	Influenza Vaccines 2013 ·JAMA Internal Medicine ·Peter Doshi	6
16	The Imperative to Share Clinical Study Reports: Recommendations from the Tamiflu Experience 2012 ·PLoS Medicine ·Peter Doshi, Tom Jefferson, Chris Del Mar	119
17	Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children breakdown → 2012 ·Cochrane Database of Systematic Reviews ·Tom Jefferson, Mark Jones, Peter Doshi, Chris Del Mar, Carl Heneghan, Rokuro Hama, Matthew Thompson	432
18	Neuraminidase inhibitors for preventing and treating influenza in healthy adults [Intervention Review] 2010 ·Tom Jefferson, Mark Jones, Peter Doshi, Chris Del Mar, Liz Dooley, Ruth Foxlee	15
19	Neuraminidase inhibitors--the story behind the Cochrane review 2009 ·BMJ ·Peter Doshi	51
20	Possible harms of oseltamivir—a call for urgent action 2009 ·The Lancet ·Tom Jefferson, Mark Jones, Peter Doshi, Chris Del Mar	28

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact